Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin

被引：0

作者：

Terpos, Evangelos ^{[1
]}

Badros, Ashraf Z. ^{[2
]}

Popat, Rakesh ^{[3
]}

Rodriguez-Otero, Paula ^{[4
]}

Farooq, Asim V. ^{[5
]}

Jeng, Bennie ^{[6
]}

Esposti, Simona Degli ^{[7
,8
]}

Lewis, Eric ^{[9
]}

Gupta, Ira ^{[9
]}

Opalinska, Joanna ^{[9
]}

Palumbo, Antonio ^{[10
]}

Trudel, Suzanne ^{[11
]}

Jadhav, Vinay ^{[9
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[2] Univ Maryland, Med Ctr, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[3] Univ Coll London Hosp NHS Fdn Trust, London, England

[4] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[6] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

[7] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England

[8] UCL Inst Ophthalmol, London, England

[9] GlaxoSmithKline, Upper Providence, PA USA

[10] GlaxoSmithKline, Zug, Switzerland

[11] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

基金：

芬兰科学院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-219

引用

页码：S160 / S160

页数：1

共 20 条

[1] Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).
Terpos, Evangelos
Badros, Ashraf
Popat, Rakesh
Rodriguez-Otero, Paula
Farooq, Asim
Jeng, Bennie
Esposti, Simona Degli
Lewis, Eric
Gupta, Ira
Opalinska, Joanna
Palumbo, Antonio
Trudel, Suzanne
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf)
Terpos, Evangelos
Badros, Ashraf
Popat, Rakesh
Rodriguez-Otero, Paula
Farooq, Asim
Jeng, Bennie
Degli Esposti, Simona
Lewis, Eric
Gupta, Ira
Opalinska, Joanna
Palumbo, Antonio
Trudel, Suzanne
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S421 - S421
[3] Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (GSK2857916; belamaf; BLENREP)
Kortuem, M.
Terpos, E.
Badros, A.
Popat, R.
Rodriguez-Otero, P.
Farooq, A.
Jeng, B.
Esposti, Degli S.
Lewis, E.
Gupta, I
Opalinska, J.
Palumbo, A.
Trudel, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 204 - 204
[4] Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin
Popat, Rakesh
Badros, Ashraf Z.
Kumar, Shaji
Rodríguez-Otero, Paula
Cohen, Adam D.
Manier, Salomon
Voorhees, Peter M.
Gay, Francesca
Rifkin, Robert M.
Martin, Thomas
Chari, Ajai
Weisel, Katja
Farooq, Asim V.
Jeng, Bennie H.
Chng, Wee Joo
Lee, Hans C.
Berdeja, Jesus
Jadhav, Vinay
Tosolini, Alessandra
Eliason, Laurie
Palumbo, Antonio
Dimopoulos, Meletios A.
Lonial, Sagar
Trudel, Suzanne
Richardson, Paul G.
Terpos, Evangelos
BLOOD, 2021, 138
[5] Impact of baseline ocular conditions on belantamab mafodotin-related corneal events in relapsed/refractory multiple myeloma
Popat, Rakesh
Kazantzi, Aikaterini
Kleinman, David
Lichenstein, Carolyn
Paka, Prani
Salter, John
Byrne, Julie
Doherty, Allison
Esposti, Simona Degli
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 65 - 66
[6] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
Lonial, Sagar
Nooka, Ajay K.
Thulasi, Praneetha
Badros, Ashraf Z.
Jeng, Bennie H.
Callander, Natalie S.
Potter, Heather A.
Sborov, Douglas
Zaugg, Brian E.
Popat, Rakesh
Degli Esposti, Simona
Byrne, Julie
Opalinska, Joanna
Baron, January
Piontek, Trisha
Gupta, Ira
Dana, Reza
Farooq, Asim V.
Colby, Kathryn
Jakubowiak, Andrzej
BLOOD CANCER JOURNAL, 2021, 11 (05)
[7] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
Sagar Lonial
Ajay K. Nooka
Praneetha Thulasi
Ashraf Z. Badros
Bennie H. Jeng
Natalie S. Callander
Heather A. Potter
Douglas Sborov
Brian E. Zaugg
Rakesh Popat
Simona Degli Esposti
Julie Byrne
Joanna Opalinska
January Baron
Trisha Piontek
Ira Gupta
Reza Dana
Asim V. Farooq
Kathryn Colby
Andrzej Jakubowiak
Blood Cancer Journal, 11
[8] Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
Popat, Rakesh
Kazantzi, Aikaterini
Kleinman, David
Lichenstein, Carolyn
Paka, Prani
Salter, John
Byrne, Julie
Doherty, Allison
Degli Esposti, Simona
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S30
[9] Durability of Response and Characterisation of Corneal events with Extended follow-up after Belantamab Mafodotin monotherapy for patients with relapsed/refractory Multiple Myeloma
Popat, Rakesh
Warcel, Dana
O'Nions, Jenny
Cowley, Anna
Smith, Sasha
Yong, Kwee
Esposti, Simona Degli
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E150 - E150
[10] Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
Popat, Rakesh
Kazantzi, Aikaterini
Farooq, Asim
Thulasi, Praneetha
Lonial, Sagar
Jakubowiak, Andrzej
Badros, Ashraf Z.
Jeng, Bennie H.
Opalinska, Joanna
Baron, January
Piontek, Trisha
Byrne, Julie
Womersley, Lynsey
Gupta, Ira
Esposti, Simona Degli
BLOOD, 2020, 136

← 1 2 →